Common Pharma, Inc.
Non-Toxic, Effective Novel Pharmaceuticals

Common Pharma's goal is to advance new active pharmaceutical agents for the treatment of serious and complicated diseases.


Our main product is an anti-IL6 new chemical entity with issued patents that has shown multi-functional properties and established a new approach in medicinal chemistry. 

 

US Patent #8,575,333 has been granted for the chemical entities.

 

European patent is granted.


Our second line of product is presented by a new formulation approach that is very effective in dermatology. 


We initiated a clinical trial for patients with Acne in June 2016. Our goal is to only claim cosmetic improvements to be able to serve this under-treated disease faster by commercialization of our product in early 2017.